1115 related articles for article (PubMed ID: 26873055)
1. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
2. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
3. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
4. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
Wattigney WA; Mootrey GT; Braun MM; Chen RT
Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
[TBL] [Abstract][Full Text] [Related]
5. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants.
Lu L; Li X; Zhang H; Liu D; Zhang Z; Wang H; Liu F; Ning Z; Li J; Pang X
Vaccine; 2015 Aug; 33(36):4653-8. PubMed ID: 25681659
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
[TBL] [Abstract][Full Text] [Related]
10. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
[TBL] [Abstract][Full Text] [Related]
12. The challenge of changing the inactivated poliomyelitis vaccine in Latin America: declaration of the Latin American Society of Pediatric Infectious Diseases (SLIPE).
Falleiros-Arlant LH; Avila-Agüero ML; Brea del Castillo J; Mariño C
Rev Chilena Infectol; 2014 Oct; 31(5):590-603. PubMed ID: 25491459
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of Two Different Sequential Schedules of Inactivated Polio Vaccine Followed by Oral Polio Vaccine Versus Oral Polio Vaccine Alone in Healthy Infants in China.
Li RC; Li CG; Wang HB; Luo HM; Li YP; Wang JF; Ying ZF; Yu WZ; Shu JD; Wen N; Vidor E
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):287-96. PubMed ID: 26407255
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months.
Sáez-Llorens X; Thierry-Carstensen B; Stoey LS; Sørensen C; Wachmann H; Bandyopadhyay AS; Nielsen PI; Kusk MV
Vaccine; 2020 May; 38(21):3780-3789. PubMed ID: 32273184
[TBL] [Abstract][Full Text] [Related]
19. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines.
Xiao Y; Daniell H
Vaccine; 2017 Sep; 35(40):5418-5425. PubMed ID: 28111147
[TBL] [Abstract][Full Text] [Related]
20. Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.
Sáez-Llorens X; Chan M; DeAntonio R; Petersen T; Olesen C; Jensen JS; Sørensen C; Ekstrand LM; Czort MK; Kristensen HH; Thulstrup N; Christoffersen DB
Vaccine; 2022 Sep; 40(40):5835-5841. PubMed ID: 36064670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
